{
    "nct_id": "NCT03023319",
    "official_title": "Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors",
    "inclusion_criteria": "* Pathologically or cytologically proven advanced, metastatic non-squamous non-small cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical cancer.\n* Measurable disease\n* Life expectancy of greater than 3 months.\n* Ability to take folic acid, vitamin B12, and dexamethasone according to protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "- Untreated or symptomatic brain metastases.",
    "miscellaneous_criteria": ""
}